QRS Solutions’ Post

𝗗𝗮𝗶𝗹𝘆 𝗡𝗲𝘂𝗿𝗼-𝗯𝗶𝘁𝗲𝘀 🧠: 🩸ONWARD Medical receives grant to study BCI in restoring movement after stroke They received a grant from The European Innovation Council and SMEs Executive Agency (EISMEA) to study its ARC-BCI therapy to restore upper limb movement after 𝘀𝘂𝗯𝗰𝗼𝗿𝘁𝗶𝗰𝗮𝗹 𝘀𝘁𝗿𝗼𝗸𝗲. ONWARD will now work closely alongside partners at CEA, EPFL, and Karolinska Institutet to investigate stroke sufferers regaining use of their arms This falls on the back of an excellent year for the team. Since reporting the first human implant of the BCI offering nearly a year ago they have... 💫Won FDA breakthrough device designation for the technology in February 💫In March, the FDA accepted the BCI into its new Total Product Lifecycle Advisory Program (TAP) 💫Received a grant from the Christopher & Dana Reeve Foundation to support an ongoing BCI study 💫Reported the third implant in September https://lnkd.in/eRTRy6AE

Following the conclusion of the ASLM Diagnostics Convention 2024, watch as our CEO, Mr. Nqobile Ndlovu, shares the driving factors behind hosting the conference and emphasizes the importance of shining a light on diagnostics and raising awareness of the role of laboratory medicine. #ASLMDiagnosticsConvention2024

NEVENT (#LSIEurope24 Innovator) was founded with a mission to eliminate patient harm caused by Retained Guidewires during the placement of vascular catheters using the Seldinger Technique. Each year, this medical error impacts over 1,500 patients, with a serious morbidity and mortality rate of 10.5%. Recognized by the Joint Commission as a Never Event in 2018, Retained Guidewires not only endanger lives but also inflict an additional $830 million in costs on physicians and healthcare systems each year. Current prevention strategies typically only identify such errors after they have occurred. In contrast, NEVENT has engineered the first effective device designed specifically to prevent the occurrence of guidewire retention. With a recent U.S. patent awarded in November 2023 and multiple international patents pending, NEVENT is at the forefront of enhancing patient safety. The company is also set to submit its NIH Grant proposal later this fall. We’re excited to announce that Anesthesiologist and Inventor, Rhodel Dacanay has been selected to present NEVENT at LSI Europe ‘24 this September 16-20 in Sintra, Portugal.

The significance of mass spectrometry in clinical workflows cannot be overstated, as it plays a vital role in enhancing patient well-being and outcomes. #future #Diagnostic #massspectrometry

“Imagine a world where someone with end-stage heart failure no longer has to worry about waiting for a transplant.” BiVACOR had an incredible year in 2024, achieving a major milestone by implanting the BiVACOR Total Artificial Heart in five patients as part of an FDA Early Feasibility Study. Ending the year on a high, the FDA approved expanding the trial to an additional 15 patients – a significant step forward in the future of heart failure treatment. We’re proud to back BiVACOR through our Healthcare Fund III, supported by the Biomedical Translation Fund (BTF), and we’re excited to continue this journey alongside them as they achieve more milestones. BiVACOR, Paul Kelly, Department of Industry, Science and Resources

🌟 TCT Conference Recap: Prof. Lei Song Unveils Phase III Results of IBS 🌟 At this year’s TCT conference, we were excited to witness Prof. Lei Song’s presentation of the IRONMAN Phase III clinical trial results for IBS! This is an exciting milestone that highlights not only the team’s research excellence but also brings an innovative solution to the field of cardiovascular treatment. 🔹 Ground-breaking Results: Phase III data show that iron-based stents maintain vascular patency with outstanding biocompatibility, significantly reducing the incidence of complications. 🔹 Better for Patients: Compared to traditional stents, iron-based stents offer enhanced degradability and biocompatibility, substantially lowering the burden of long-term follow-up and providing a safer, more effective treatment option for patients. 🔹 Gratitude for the Team's Dedication: Prof. Runlin Gao and Prof. Lei Song with his team have demonstrated rigorous scientific dedication and perseverance, driving progress in cardiovascular medical technology and making high-quality care more accessible. A huge thank you to all the researchers, clinicians, and patients involved in this project! We look forward to seeing these findings swiftly translated into clinical practice, benefiting more patients. #CardiovascularInnovation #TCT2024 #IronBasedScaffold #MedTech #ClinicalTrials #HealthTech #Biotyx #IBS #IronBasedScaffold

ON-DEMAND // View the second installment of our webinar series with Precision For Medicine, focusing on optimizing immunohistochemistry (IHC) validation and regulatory strategies. This session explores in-depth the essential validation and regulatory strategies for IHC, providing crucial insights into the regulatory landscape and validation processes necessary for successful clinical trials. Watch it here: https://lnkd.in/gS3WemA9

Looking forward participating to ISC2025! Join me on February 06th at 6.00 pm at the poster session to hear more about our latest preclinical data in ICH with BIOX-101!

Join us at ADLM to learn about CgA and how automation improves testing performance

Join us at HRS2024! Booth 453    Session Title: PO-484335 Poster Session VI – Ablation Session Date and Time: May 19, 2024 from 9:30 AM to 11:30 AM  Presentation: Paroxysmal Atrial Fibrillation Treated by A Pulsed- Field Ablation System Using ACircular Catheter with Variable Diameter  （One-Year Outcome of PF-Beat-AF Clinical Trial）